Primary Myelofibrosis Clinical Trial
Official title:
A Phase II Study of Fedratinib and Nivolumab Combination in Patients With Myelofibrosis and Resistance or Suboptimal Response to JAK-inhibitor Treatment
A multicenter, open-label, single arm, phase II study investigating the clinical efficacy of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment
The FRACTION trial will evaluate the clinical efficacy of Fedratinib and Nivolumab combination therapy in patients with primary and secondary myelofibrosis based on the consensus criteria of the International Working Group for Myelofibrosis Research and treatment (IWG-MRT), extended by the criterion RBC-transfusion independence (RBC-TI). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01178281 -
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
|
Phase 3 | |
| Not yet recruiting |
NCT06327100 -
Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
|
Phase 2 | |
| Active, not recruiting |
NCT00095784 -
Decitabine in Treating Patients With Myelofibrosis
|
Phase 2 | |
| Recruiting |
NCT02897297 -
Myeloproliferative Neoplastic Diseases Observatory From Brest
|
||
| Terminated |
NCT02091752 -
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
|
Phase 2 | |
| Completed |
NCT01445769 -
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
|
Phase 2 | |
| Completed |
NCT01233921 -
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
|
N/A | |
| Unknown status |
NCT01298934 -
LBH589 (Panobinostat) for the Treatment of Myelofibrosis
|
Phase 1/Phase 2 | |
| Terminated |
NCT00387426 -
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
|
Phase 2 | |
| Completed |
NCT05044026 -
A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis
|
||
| Active, not recruiting |
NCT03952039 -
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
|
Phase 3 | |
| Active, not recruiting |
NCT02530619 -
Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
|
N/A | |
| Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
| Completed |
NCT01731951 -
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
|
Phase 2 | |
| Not yet recruiting |
NCT06468033 -
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
|
Phase 3 | |
| Completed |
NCT01371617 -
A Phase 2 Study With IPI-926 in Patients With Myelofibrosis
|
Phase 2 | |
| Active, not recruiting |
NCT02251821 -
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
|
Phase 2 | |
| Active, not recruiting |
NCT04446650 -
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
|
Phase 1/Phase 2 | |
| Completed |
NCT01981850 -
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
|
Phase 2 | |
| Withdrawn |
NCT04283526 -
Study of Select Combinations in Adults With Myelofibrosis
|
Phase 1 |